Stephen M. Ansell, MD, PhD, discusses the data regarding the recent approval of brentuximab vedotin (Adcetris) from the phase III ECHELON-2 trial presented at the 2018 American Society of Hematology Annual Meeting and considers its impact on the CD30-positive treatment landscape.
